Zynex (ZYXI) to Release Quarterly Earnings on Monday

Zynex (NASDAQ:ZYXI) will likely be releasing its Q4 2025 results after the market closes on Monday, April 27th. Analysts expect Zynex to post earnings of ($0.15) per share and revenue of $22.60 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, April 9, 2026 at 4:00 PM ET.

Zynex Stock Performance

NASDAQ:ZYXI opened at $0.13 on Monday. The stock has a market cap of $3.80 million, a P/E ratio of -0.05 and a beta of 0.99. The company has a current ratio of 0.47, a quick ratio of 0.32 and a debt-to-equity ratio of 0.56. The stock’s 50-day moving average is $0.12 and its 200-day moving average is $0.49. Zynex has a 1-year low of $0.12 and a 1-year high of $8.45.

Institutional Investors Weigh In On Zynex

Institutional investors have recently bought and sold shares of the stock. Engineers Gate Manager LP bought a new position in Zynex during the 2nd quarter valued at $32,000. XTX Topco Ltd purchased a new position in Zynex during the second quarter worth about $47,000. Sender Co & Partners Inc. purchased a new position in Zynex during the second quarter worth about $67,000. Bridgeway Capital Management LLC grew its position in Zynex by 59.5% in the 3rd quarter. Bridgeway Capital Management LLC now owns 67,000 shares of the company’s stock worth $97,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Jane Street Group LLC grew its position in Zynex by 239.9% in the 1st quarter. Jane Street Group LLC now owns 53,377 shares of the company’s stock worth $117,000 after purchasing an additional 37,673 shares in the last quarter. Institutional investors own 29.68% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Zynex in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Zynex has a consensus rating of “Hold” and a consensus target price of $4.90.

Zynex Company Profile

Zynex, Inc is a medical device company engaged in the design, development, manufacture and sale of non-invasive therapeutic and patient monitoring equipment in the United States. Headquartered in Englewood, Colorado, the company focuses on delivering FDA-cleared solutions aimed at pain management, neurological rehabilitation and remote patient monitoring. Zynex’s portfolio is structured to address the needs of healthcare providers, outpatient clinics and patients receiving care in their homes.

The company’s core product offerings include electrotherapy devices—such as transcutaneous electrical nerve stimulation (TENS) and neuromuscular electrical stimulation (NMES) systems—designed to alleviate pain and assist in muscle recovery.